



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Ovine herpesvirus-2 encoded microRNAs target virus genes involved in virus latency

Citation for published version:

Riaz, A, Dry, I, Levy, C, Hopkins, J, Grey, F, Shaw, D & Dalziel, R 2014, 'Ovine herpesvirus-2 encoded microRNAs target virus genes involved in virus latency', *Journal of General Virology*, vol. 95, no. 2, pp. 472-480. <https://doi.org/10.1099/vir.0.059303-0>

Digital Object Identifier (DOI):

[10.1099/vir.0.059303-0](https://doi.org/10.1099/vir.0.059303-0)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Journal of General Virology

Publisher Rights Statement:

This is an author manuscript that has been accepted for publication in Journal of General Virology, copyright Society for General Microbiology, but has not been copy-edited, formatted or proofed. Cite this article as appearing in Journal of General Virology. This version of the manuscript may not be duplicated or reproduced, other than for personal use or within the rule of 'Fair Use of Copyrighted Materials' (section 17, Title 17, US Code), without permission from the copyright owner, Society for General Microbiology. The Society for General Microbiology disclaims any responsibility or liability for errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final copy-edited, published article, which is the version of record, can be found at <http://vir.sgmjournals.org>, and is freely available without a subscription 12 months after publication.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 Ovine herpesvirus-2 encoded microRNAs target virus genes involved in virus
2 latency.

3

4 Aayesha Riaz, Inga Dry, Claire S. Levy¹, John Hopkins, Finn Grey, Darren J. Shaw and Robert G.
5 Dalziel*

6 *Corresponding author. Mailing address: The Roslin Institute & R(D)SVS, University of Edinburgh,
7 Easter Bush Veterinary Campus, Roslin, Midlothian, EH25 9RG U.K. Phone: +44 1316519233. E-
8 mail address: bob.dalziel@ed.ac.uk

9 ¹ Current Address: The Scripps Research Institute, 10550 North Torrey Pines Road, BCC-239, La
10 Jolla, California 92037

11

12 Running Title: OvHV-2 miRNA targets.

13

14

15 Summary word count: 236

16 Manuscript word count: 4723

This is an author manuscript that has been accepted for publication in Journal of General Virology, copyright Society for General Microbiology, but has not been copy-edited, formatted or proofed. Cite this article as appearing in Journal of General Virology. This version of the manuscript may not be duplicated or reproduced, other than for personal use or within the rule of 'Fair Use of Copyrighted Materials' (section 17, Title 17, US Code), without permission from the copyright owner, Society for General Microbiology. The Society for General Microbiology disclaims any responsibility or liability for errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final copy-edited, published article, which is the version of record, can be found at <http://vir.sgmjournals.org>, and is freely available without a subscription 12 months after publication.

17 **Summary**

18 Herpesviruses encode miRNAs that target both virus and host genes; however their role in herpesvirus
19 biology is poorly understood. We previously identified eight miRNAs encoded by OvHV-2; the
20 causative agent of malignant catarrhal fever (MCF) and have now investigated the role of these
21 miRNAs in regulating expression of OvHV-2 genes that play important roles in virus biology. ORF
22 20 (cell cycle inhibition), ORF 50 (reactivation) and ORF 73 (latency maintenance) each contain
23 predicted targets for several OvHV-2 miRNAs. Co-transfection of miRNA mimics with luciferase
24 reporter constructs containing the predicted targets showed the 5' UTRs of ORF 20 and ORF 73
25 contain functional targets for ovhv-miR-2 and ovhv2-miR-8 respectively, and the 3'UTR of ORF 50
26 contains a functional target for ovhv2-miR-5. Transfection of BJ1035 cells (an OvHV-2 infected
27 bovine T cell line) with the relevant miRNA mimic resulted in a significant decrease in ORF 50 and a
28 smaller but non-significant decrease in ORF 20. However, we were unable to demonstrate a decrease
29 in ORF 73. MCF is a disease of dysregulated lymphocyte proliferation, miRNA inhibition of ORF 20
30 expression may play a role in this aberrant lymphocyte proliferation. The proteins encoded by ORFs
31 50 and 73 play opposing roles in latency, it has been hypothesized that miRNA-induced inhibition of
32 virus genes acts to ensure that fluctuations in virus mRNA levels do not result in reactivation in
33 conditions that are unfavourable for viral replication, our data would support this hypothesis.

34

35 **Introduction**

36 Malignant catarrhal fever (MCF) is a fatal disease of cattle and other ruminants caused by viruses in
37 the genus *Macavirus* of the subfamily *Gammaherpesvirinae* (Russell *et al.*, 2009). The disease occurs
38 as a result of infection of susceptible hosts by contact with an asymptomatic carrier species that acts
39 as a virus reservoir. Ovine herpesvirus-2 (OvHV-2) sub-clinically infects most sheep and is the major
40 cause of MCF worldwide (Russell *et al.*, 2009). In both sheep and cattle, OvHV-2 infects CD2⁺ T
41 lymphocytes (Meier-Trummer *et al.*, 2010; Schock *et al.*, 1998) but only in cattle does virus infection
42 cause dysregulation of lymphoid cell function leading to uncontrolled proliferation, cytotoxicity and
43 MCF disease. The proliferation of infected bovine T cells is dependent on the cytokine interleukin-2
44 (IL-2) and immortalized T cell lines can be cultured from affected cattle. The infected bovine T cells
45 do not support productive virus replication and have been described as large granular lymphocytes
46 (LGLs) (Reid *et al.*, 1989) in part due to expression of perforin (Nelson *et al.*, 2010); and unlike
47 sheep, infected cattle cannot transmit the virus to other susceptible hosts (Russell *et al.*, 2009). The
48 mechanism by which OvHV-2 induces MCF in cattle is unknown; virus-induced cytopathology is
49 thought not to be involved in lesion development and it has been proposed that tissue damage arises
50 from non-antigen specific, MHC unrestricted cytotoxicity of the virus-infected LGLs (Cook &
51 Splitter, 1988).

52 MicroRNAs (miRNAs) are short (21-23nt) RNAs that act as post-transcriptional inhibitors of gene
53 expression. Cellular miRNAs expressed in the nucleus are derived from primary transcripts (pri-
54 miRNAs) that are processed by the enzyme Drosha to form a shorter precursor miRNA (pre-miRNA).
55 These pre-miRNAs are exported from the nucleus and once in the cytoplasm are further cleaved by
56 the enzyme Dicer to produce a transient double-stranded precursor; where one strand is designated the
57 miRNA or guide strand and the complementary strand is designated the miRNA* or passenger strand.
58 The miRNA is stably incorporated into the RNA-induced silencing complex and guides it to the target
59 mRNA, which represses translation by a number of mechanisms including mRNA degradation and
60 inhibition of translation. The interaction of miRNAs with target mRNAs is mediated by a seed region,
61 nucleotides 2-7 or 2-8 at the 5' end of the miRNA (Bartel, 2009) Most miRNA targets identified to date
62 are present in the 3'UTR of mRNAs, however some miRNAs have been reported that functionally
63 target the 5'UTR (Grey *et al.*, 2010; Tay *et al.*, 2009).

64 To date, over 250 virus-encoded miRNAs have been identified, the majority from herpesviruses
65 (Grundhoff & Sullivan, 2011). Herpesvirus-encoded miRNAs have been shown to regulate both
66 cellular and viral gene expression and to influence cell processes including proliferation. In Marek's
67 disease virus (MDV), the deletion of a single virus-encoded miRNA abrogates virus-induced cellular
68 transformation (Zhao *et al.*, 2011) and in Epstein Barr virus (EBV) a cluster of miRNAs has been
69 implicated in controlling virus-induced B cell proliferation and transformation (Feederle *et al.*, 2011a;

70 Feederle *et al.*, 2011b; Seto *et al.*, 2010). We have previously demonstrated that OvHV-2 encodes at
71 least eight miRNAs (Levy *et al.*, 2012) expressed within the immortalized bovine LGL line, BJ1035;
72 and hypothesize that these play a critical role in MCF pathogenesis. In order to investigate the role of
73 virus-encoded miRNAs in OvHV-2 pathogenesis it is necessary to identify their viral and cellular
74 targets. In this study we investigated the role of OvHV-2 encoded miRNAs in regulating selected
75 virus gene expression. There is no *in vitro* infection system for studying OvHV-2; the only cells in
76 which virus gene expression can be studied are immortalized LGL lines like BJ1035 (Levy *et al.*,
77 2012). All cells in these LGL lines are virus genome positive and in the majority OvHV-2 is latent;
78 however, some lytic cycle gene expression occurs in a small proportion of the cells (Rosbottom *et al.*,
79 2002; Thonur *et al.*, 2006).

80 **Results**

81 **Prediction of OvHV-2 encoded miRNA targets in the OvHV-2 genome.**

82 Potential miRNA targets within the OvHV-2 genome were initially identified by scanning the entire
83 OvHV-2 genome using BLASTN (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) to align the sequences
84 complementary to the ovhv2-miRs in the OvHV-2 genome (GenBank, AY839756) (Hart *et al.*, 2007).
85 Targets were then mapped to the 5'UTR or 3'UTR of OvHV2 genes. Only a small number of OvHV-
86 2 mRNAs have been mapped previously therefore for the majority of genes the 5'UTRs were
87 considered to span the region from the start codon to the predicted TATA box. For 3'UTRs the region
88 from the stop codon to the predicted polyadenylation site was used. This analysis identified potential
89 targets in 33 OvHV-2 genes, representing all classes of virus gene; immediate early, early and late,
90 and both structural and non-structural proteins.

91 For validation of predicted targets we focussed on genes/proteins predicted to play important roles in
92 virus biology and pathogenesis. We chose to analyse targets present in the 5' or 3'UTR of three virus
93 genes, ORF 20, ORF 50 and ORF 73. ORF 20 has been shown to induce cell cycle arrest in other
94 herpesviruses (Nascimento *et al.*, 2009), and the other two genes encode proteins that play contrary
95 roles in virus latency. ORF 50 is crucial for virus reactivation from latency and ORF 73 is important
96 for the maintenance of latency (Ackermann, 2006). The positions of the predicted miRNA target sites
97 in ORF 20, ORF 50 and ORF 73 are detailed in Table 1.

98 miRNAs function by targeting expressed mRNAs, ORF 20 and 50 are only predicted open
99 reading frames from the genomic sequence; and the ORF 73 transcript is only partially mapped
100 (Coulter & Reid). In this study we confirmed the existence of these three virus ORFs as transcripts,
101 including the miRNA target sites, using an RT-PCR strategy.

102 The annotated OvHV-2 genome predicts that ORF 20 overlaps with both ORF 19 and ORF 21 (Fig.
103 1A). To allow detection of ORF 20 only, cDNA synthesis was primed using a gene-specific primer
104 located 406 bp upstream (42530-41549) of the ORF 19 TATA box (41106). This primer will not
105 prime ORF 21 mRNA as it is the same sense as the ORF 21 transcript. Fig. 1B shows the 118 bp
106 amplicon, the sequence of which was 100% identical to the predicted ORF 20 sequence (39294 –
107 41641) and includes the target sequence (41617 – 41635) for ovhv-2-miR-2 (Fig. 1B).

108 The ORF 50 and Ov6 transcripts are transcribed in the same direction, with the Ov6 TATA box lying
109 94 bp downstream of the ORF 50 poly A site. ORF 50 is spliced and ORF 49 lies within the ORF 50
110 intronic sequence transcribed in the opposite direction (Fig. 1A). We were unable to prime cDNA
111 synthesis efficiently using an ORF 50 gene specific primer due to the limited number of nucleotides
112 between the predicted target sequence and the poly A site, we therefore used both oligo dT and
113 random primers to prime cDNA synthesis. PCR primers (78080-78099 and 79205-79181) were
114 designed to generate an 1101bp amplicon, from the middle of the second exon of ORF 50 to the poly
115 A site. The 3' primer (79025 - 79181) is approximately 1900 bp and 82 bp upstream of ORF 49 and
116 Ov6 TATA boxes respectively; and the 5' primer (78080 - 78099) is 118 bp upstream of the Ov6
117 TATA box and 2304 bp upstream of the Ov6 polyA site. Fig. 1C shows the 1101 bp amplicon the
118 sequence of which was 100% identical to the predicted ORF 50 and included the target sequence
119 (79205 - 79181) for ovhv-2-miR-2.

120 ORF 73 lies downstream of the ORF 75 transcript and is transcribed in the same direction (Fig. 1A).
121 The annotated OvHV-2 genome (GenBank, AY839756) (Hart *et al.*, 2007) states the 5' terminus of
122 the ORF 73 transcript at nt 121049, 31 bp upstream of the predicted poly A site for ORF 75. We used
123 both oligo dT and random primers to prime cDNA synthesis. PCR primers (120514-120534 and
124 121060-121041) generates a 536 bp amplicon from within the coding sequence of ORF 73 to the
125 predicted end of ORF 73 mRNA. Fig. 1D shows this 536 bp amplicon, the sequence of which was
126 100% identical to the predicted ORF 73 and includes the target sequence (120817-120839) for ovhv-
127 2-miR-8.

128 **Inhibition of gene expression**

129 BJ1035 is a mixed population of cells with respect to virus life cycle; the majority are latently infected
130 but a small proportion express early and late virus genes (Rosbottom *et al.*, 2002; Thonur *et al.*,
131 2006). OvHV-2 miRNAs may be also differentially expressed in the proportion of cells in culture in
132 which the virus is latent compared to those cells where the virus is reactivating making analysis of
133 inhibition of gene expression following introduction of exogenous miRNAs complex. We therefore
134 initially assessed the ability of the ovhv2-miRNAs to interact with their predicted targets using a
135 luciferase expression assay.

136 We have previously shown that insertion of a predicted 5'UTR downstream of an exogenous
137 promoter, e.g CMV IE, can result in the expression of transcripts in which the start site does not
138 reflect that of the native transcript (Grey *et al.*, 2010). In keeping with our previous studies, when
139 analysing targets in 5'UTRs we cloned a region approximately 1000bp upstream of the AUG in an
140 attempt to allow correct expression from the natural promoter. For all experiments a luciferase
141 expressing vector lacking OvHV-2 sequences was used to investigate off- target effects: no significant
142 reduction in luciferase expression was seen using any of the ovhv-2-miRs.

143 The 5'UTR of ORF 20 contained a predicted target site for ovhv2-miR-2, (Table 1;Fig. 3). BHK-21
144 cells were co-transfected with reporter constructs and miRNA mimics as described and luciferase
145 expression levels were measured. The combination of the ORF 20 5'UTR reporter and ovhv2-miR-2
146 resulted in a 57.5 (± 10) % reduction ($p \leq 0.03$) in luciferase expression using 100 nM mimics (Fig.
147 2a) compared to control miRNA. The same degree of inhibition was observed using 50nM mimics
148 (data not shown). OvHV2-miR-2 inhibited luciferase expression by 47.5(± 15) % ($p \leq 0.003$) even after
149 the mutation of the predicted target site in the 5'UTR (Fig. 2A), suggesting that inhibition was not due
150 to interaction of ovhv2-miR-2 with the predicted target sequence. The 3'UTR of ORF 50 was
151 predicted to contain a target site for ovhv2-miR-5 (Table 1, Fig. 3) the combination of ORF 50 3'UTR
152 and ovhv2-miR-5 mimic resulted in a 45 (± 10) % reduction ($p \leq 0.001$) in luciferase expression (Fig.
153 2B) compared to control miRNA. Mutation of the target site from the 3'UTR abrogated this
154 inhibition.

155 The 5'UTR of ORF 73 was predicted to contain two separate sites for ovhv2-miR-8 (Table 1, Fig. 3).
156 The combination of 5'UTR of ORF 73 and ovhv2-miR-8 mimic resulted in a 45(± 8) % decrease ($p \leq$
157 0.001) in luciferase expression (Fig 2C). Mutation of either of the predicted ovhv2-miR-8 target sites
158 abolished the inhibitory effect of ovhv2-miR-8.

159 To further investigate inhibition of the expression of these OvHV-2 genes by the ovhv2-miRs we
160 developed RT-qPCR assays for ORF 20, 50 and 73 transcripts. BJ1035 cells were transfected with the
161 relevant ovhv2-miR mimics or control miRNA for 24 or 48h at which point cells were harvested,
162 RNA isolated and qPCR carried out. We were able to demonstrate a 42(± 15) % reduction in levels of
163 ORF 50 transcript following transfection with ovhv2-miR-5 (Fig. 4a, $P=0.042$). Although there
164 appeared to be a 12.8 (± 13) % reduction in levels of ORF 20 transcript following transfection with
165 ovhv2-miR-2 (Fig. 4b), this was not significant ($P=0.532$). Furthermore, we were unable to
166 demonstrate any reduction in levels of ORF 73 transcript following transfection with ovhv2-miR-8 (+
167 7.3(± 13.9) %) (Fig. 4c, $P=0.532$).

168 Discussion

169 OvHV-2 induced malignant catarrhal fever in susceptible hosts is a disease of dysregulated
170 lymphocyte proliferation and cell function. However, these susceptible hosts cannot transmit the
171 virus. In contrast, infection of carrier hosts is asymptomatic, but these are infectious. A previous study
172 has shown that this virus expresses at least eight miRNAs (Levy *et al.*, 2012). In this study we
173 investigated the control of expression of three virus genes important for control of cell cycle (ORF 20)
174 and virus latency (ORF 50 and ORF 73) by virus-encoded miRNAs.

175 The 3' UTR of ORF 50 was predicted to be targeted by ovhv2-miR-5. This interaction was confirmed
176 by both the luciferase assay and by inhibition of ORF 50 miRNA levels in BJ1035 cells transfected
177 with ovhv2-miR-5. Thus we have demonstrated that expression of ORF 50, whose main role is to
178 drive reactivation from latency, can be inhibited by a viral encoded miRNA.

179 The 5'UTR of ORF 20 was predicted to contain one site recognised by ovhv2-miR-2. OvHV2-miR-2
180 did inhibit luciferase expression; however mutation of the predicted site did not abolish this inhibition.
181 Thus, whilst we have demonstrated that ovhv2-miR-2 inhibits expression of a transcript containing
182 the 5'UTR of ORF 20, we cannot definitively show that this inhibition is a consequence of its
183 interaction with the target site predicted in the original analysis. We also investigated the ability of
184 ovhv2-miR-2 to inhibit ORF 20 expression in BJ1035 cells. We were able to demonstrate a small
185 reduction in ORF 20 mRNA levels in BJ1035 cells transfected with this ovhv2-miR-2; however was
186 not statistically significant.

187 ORF 73 was predicted to contain two sites recognised by the ovhv2-miR-8 seed sequence located nine
188 bases apart (Fig. 3). ovhv2-miR-8 was able to inhibit gene expression in the luciferase assay and
189 mutation of either of these sites resulted in loss of inhibition. Further analysis of the binding of ovhv2-
190 miR-8 to this region using RNAhybrid showed that site 1 was predicted to bind the miRNA with high
191 efficiency, but RNAhybrid did not identify site 2. Site 2 lies in the region that is likely to interact with
192 the 3' end of a miRNA interacting at site 1. It is therefore likely that site 1 is functional and that the
193 loss of inhibition seen when site two is mutated is due to loss of non-seed sequence interactions. We
194 were unable to demonstrate any reduction in ORF 73 mRNA levels following transfection of ovhv2-
195 miR-8 into BJ1035 cells.

196 The inability to demonstrate inhibition of ORF 20 and ORF 73 expression in BJ1035 cells may be due
197 to a number of factors e.g. the inherent variability within BJ1035 cells could result in variation in
198 baseline levels of virus gene expression or the ovhv2-miRs may inhibit translation (the luciferase
199 assay measured protein levels) of ORFs 20 and 73 without significantly affecting mRNA levels. ORF
200 73 is the main latency associated protein and so will be expressed in the majority of BJ1035 cells. Our
201 transfection efficiency for BJ1035s is approximately 40-45% (data not shown) it is possible that the
202 level of inhibition obtained is not sufficient to be seen under these experimental conditions.

203 In all three classes of herpesvirus, homologues of ORF 20 (the UL24 family) have been shown to
204 induce cell cycle arrest and inactivate the cyclin B/cdc2 complex (Nascimento *et al.*, 2009). The
205 conservation of the structure and function of these proteins during herpesvirus evolution strongly
206 suggests that they are important in herpesvirus biology (Nascimento *et al.*, 2009 Using ORF 20
207 deletion mutants of MHV Nascimento et al {Nascimento, 2011 #2962) also demonstrated that ORF
208 20 is not essential for virus replication, there was a delay in virus clearance from the lungs of animals
209 infected with the mutant virus and the mutants established latency normally. The role, if any, of ORF
210 20 in MHV pathogenesis is therefore not clear. A recent study has shown that viral cyclins play a key
211 role in control of latency and reactivation of the gammaherpesvirus MHV-68 (Lee *et al.*, 2012).
212 Different mammalian cyclins could substitute for some of the functions of the MHV-68 cyclins with
213 different cyclins mediating persistence or reactivation (Lee *et al.*, 2012). It is possible that changes in
214 expression of ORF 20, mediated in part by ovhv2-miRNAs, could result in a change in the cyclin
215 expression profile in infected cells influencing the balance between productive and latent life cycles.
216 A major part of MCF pathogenesis is uncontrolled proliferation of the infected LGLs, whose aberrant
217 cytotoxic function leads to pathology. Inhibition of ORF 20 expression by ovhv2- miR-2 may down-
218 regulate an ORF 20 mediated block to the cell cycle contributing to the dysregulated lymphocyte
219 proliferation in susceptible hosts. OvHV-2 miRNAs were identified as being expressed in a bovine
220 cell line, their expression pattern in infected ovine cells is unknown, however it is possible that a
221 difference in the regulation of these miRNAs in ovine and bovine cells may result in differences in
222 expression of ORF 20 leading to the observed differences in the outcome of OvHV-2 infection in
223 cattle and sheep.

224 ORF 50 is a homologue of the replication and transcription activator (RTA) of EBV and Kaposi's
225 sarcoma herpesvirus (KSHV). In KSHV, the virus encoded miR-K5 and miR-K9 have antagonistic
226 effects on latency. miR-K5 attenuates expression of RTA leading to a reduction in reactivation whilst
227 miR-K9 targets BCLAF-1, a host transcription factor that is associated with reduced viral replication
228 (Ziegelbauer *et al.*, 2009). Using a PARclip approach Gottwein *et al.* (Gottwein & Cullen, 2010)
229 have reported that ORF 73 of KSHV is targeted by KSHV miR-K10/miR-142- 3p. Deletion of three
230 EBV-encoded miRNAs has been shown to result in a significant increase in expression of virus latent
231 genes (Feederle *et al.*, 2011a; Feederle *et al.*, 2011b; Seto *et al.*, 2010) and Riley *et al.* (Riley *et al.*,
232 2012) have shown that EBV-encoded miRNAs target virus-encoded, latency-associated genes and
233 suggested that these miRNAs play a role in control of EBV latency. The OvHV-2 immortalized LGL
234 cell line, BJ1035 is a mixed population of cells with respect to virus life cycle; the majority are
235 latently infected but a small proportion express early and late virus genes (Rosbottom *et al.*, 2002;
236 Thonur *et al.*, 2006). Thus, OvHV-2 miRNAs may be differentially expressed in the proportion of
237 cells in culture in which the virus is latent compared to those cells where the virus is reactivating.

238 The proteins encoded by ORF 50 and ORF 73 play important, but contrary roles in relation to latency;
239 ORF 50 is critical for virus reactivation and ORF 73 is important in maintenance of viral latency
240 (Ackermann, 2006). Bellare and Ganem (Bellare & Ganem, 2009) proposed that miRNA-induced
241 inhibition of virus genes is not the sole regulator of reactivation/latency but rather that they ensure
242 that fluctuations in virus mRNA levels do not result in reactivation in conditions that are unfavourable
243 for viral replication, i.e. the miRNAs act as a type of rheostat to control the levels of virus gene
244 expression. The apparent contradiction of having miRNAs that act to both inhibit and encourage
245 reactivation expressed in the same cell line can be explained by considering the mixed nature of the
246 BJ1035 line. The differential expression of individual virus miRNAs in individual cells could respond
247 to changes in the cellular environment acting to regulate virus gene expression . The factors which
248 determine the maintenance of, or reactivation from, latency, are complex, by demonstrating miRNA
249 mediated control of both “pro and anti- reactivation genes” our data adds support to the hypothesis
250 that miRNAs represent an additional layer of control exerted by the virus to control the latent state.

251

252 **Methods**

253 **Target identification.** Potential miRNA targets within the OvHV-2 genome were identified using
254 BLASTN (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) to align the sequences complementary to the
255 ovhv2-miRs in the OvHV-2 genome (GenBank, AY839756) (Hart *et al.*, 2007). Targets were mapped
256 to the 5'UTR or 3'UTR of OvHV2 genes. Only a small number of OvHV-2 mRNAs have been
257 mapped previously therefore, for the majority of genes, the 5'UTRs were considered to span the
258 region from the start codon to the predicted TATA box. For 3'UTRs the region from the stop codon to
259 the predicted polyadenylation site was used. Sites chosen for validation were also analysed by
260 RNAhybrid (Rehmsmeier *et al.*, 2004) allowing no G:U pairing in the seed sequence and a helix
261 constraint of nucleotides 2 to 8.

262 **Cell culture.** Baby hamster kidney cells (BHK-21) were cultured in Glasgow's minimum essential
263 medium (Gibco) supplemented with 10% new born calf serum, 1% v/v Penicillin/Streptomycin, 1%
264 v/v L-glutamine (Sigma) and 10% v/v tryptose phosphate broth. BJ1035 cell were grown in
265 suspension in Iscove's Modified Dulbecco's Medium (Invitrogen) (Hart *et al.*; 2007) supplemented
266 with 10% v/v FCS, 1% v/v penicillin/streptomycin and 350 U ml⁻¹ Proleukin (IL-2) (Novartis
267 Pharmaceutical) and cultured at 37°C with 5% CO₂.

268 **Cloning of target sites.** Sequences spanning the 3' and 5' UTRs of the selected genes were amplified
269 by PCR (Fig S1). For 3'UTRs the region from the stop codon to the predicted poly A site was
270 amplified, for analysis of 5'UTRs approximately 1000 bp upstream of the ATG was amplified,

271 3'UTRs were cloned into the psiCHECKTM-2 Vector (Promega) downstream of a renilla luciferase
272 reporter gene (Rluc) and 5'UTRs into the pGL4.10 vector (Promega) upstream of a firefly luciferase
273 reporter gene (Fluc).

274 **Transfection.** BHK-21 cells (n=6) were co-transfected with reporter vectors (1.5 µg) with or without
275 the 5' or 3'UTR of interest and with 50 nM or 100 nM mimic miRNAs (miScript miRNA Mimics,
276 Qiagen) or control miRNA (AllStars Negative Control siRNA, Qiagen) using Lipofectamine 2000
277 (Invitrogen) (Mimic sequences: ovhv2-miR-2 , 5'-AUCUUGGACGCAUCUGUCAGUAG-3'; ovhv2-
278 miR-5 , 5'-UGAAGUUACAGCUGCACCUGGAU-3'; ovhv2-miR-8 ,
279 5'- UGGCUCAGCGUGACUGCUCUUC-3'). After 24 h, samples were harvested and luciferase
280 levels assessed using the Dual-Luciferase Reporter Assay System (Promega). For psiCheck (3'UTR)
281 based vectors Rluc (target) expression was normalized to Fluc expression from the same plasmid. For
282 pGL4.10 (5'UTR) based vectors, cells were co-transfected with the pRL vector (Promega) to allow
283 normalization of Fluc expression. BJ1035 cells were prepared for transfection by density –gradient
284 centrifugation using lymphoprep (Axis-Shield) and re-suspended at a concentration of 1x 10⁶ cells in a
285 final volume of 100ul of solution V (Lonza). 200 nM of mimic or control miRNA were transfected
286 into the prepared cells using program X-001 of Nucleofector II (Lonza). Transfected cells (n=3) were
287 incubated for 24 hr in BJ1035 media prior to RNA extraction.

288 **Site directed mutagenesis.** Site directed mutagenesis was performed using the Quick Change Site-
289 Directed Mutagenesis (Stratagene) protocol. Primers for mutagenesis (HPLC purified, Eurofins MWG
290 Operon, Germany) were designed such that each primer was 42-45 nt in length, with a T_m of >78°C.
291 (Table S1). All mutations were confirmed by sequencing.

292 **cDNA synthesis.** RNA was isolated from BJ1035 cells using an RNeasy kit (Qiagen). 1 µg RNA was
293 digested with RQ1 DNase (Promega) for 30 min at 37 °C. For analysis of ORF 20, cDNA was primed
294 with 250 ng or 66 ng of specific primer (41530 - CTGAAACATGGCCTCCAAC -41549). For
295 analysis of ORF 50, cDNA was primed using 250 ng oligo dT primer or random primers (Promega;
296 equivalent to 0.5 µg.µg⁻¹ RNA). cDNA was synthesized using AMV reverse transcriptase for 1 hr at
297 42 °C (oligo dT and specific primer) or 37 °C (random primer).

298 **RT-PCR analysis of transcripts.** ORF 20 cDNA was amplified with primer pair
299 TTCATAGTCACTGTTGTCC and CTGAAACATGGCCTCCAAC (nt 41617-41635 and 41530-
300 41549). ORF 50 cDNA was amplified with the primer pair CCCCAACAAGTCAGCATTTT and
301 CACTTTTATTTTAACATCACAAACC (nt 78080-78099 and 79205-79181). ORF 73 cDNA was
302 amplified with the primer pair CCACTTCGTAAAAGCACCATT and
303 GTAATCCTGCCCCAGCTGTA (nt 120514-120534 and 121060-121041). PCR reactions contained
304 8 pM primers, 120 µM dNTPs, 1 U HotStar Taq plus (Qiagen) in a final reaction volume of 25 µl.

305 Following an initial denaturation of 5 min at 95 °C, 40 cycles (30 s at 95 °C, 30 s at 58 °C and 1 min
306 15 s at 72 °C) were performed prior to a final extension of 5 min at 72 °C. 100 ng of BJ1035 DNA
307 was used as a positive control for the PCR. Samples were run on a 2% agarose gel and visualized,
308 extracted, cloned into pCR2.1-Topo (Invitrogen) and sequenced.

309 **RT-qPCR.** RNA was isolated using an RNeasy kit (Qiagen). 1 µg of RNA was digested with RQ1
310 Dnase (Promega) for 30 min at 37 °C. cDNA was primed using 250ng Oligo dT primer (Promega;
311 equivalent to 0.5 µg/µg RNA) and synthesized using AMV reverse transcriptase for 1 hr at 42 °C.
312 Semi-quantitative PCR was performed on a Rotorgene Q machine (35 cycles of 15 s 95 °C, 30 s 58 °C
313 and 30 s 72 °C) using SensiFAST™ SYBR Hi-ROX One-Step master mix (Bioline), 2µl of diluted
314 cDNA (1:10) and specific primers for GAPDH (Gossner *et al.*, 2009), ORF 20
315 (CACTACCCAGCGCTCTTCC (41125-41143); TTGTACCCAACCCCATCAAG (41237-41218);
316 ORF 50 (CCCCAACAAGTCAGCATTTT (78080-78099); TCAGGGGTGACTCCAATG (78267-
317 78250) and ORF 73 (CAG GGCAAAACGTAA AAAGC (119367-119348); GTGTGGAGC
318 GTTAGGATTG (119223-119241) at a final concentration of 8 pM in a final reaction volume of 20
319 µl. Transcript levels were normalised to GAPDH and the relative expression was calculated using $2^{-\Delta\Delta Ct}$
320 (Livak & Schmittgen, 2001). Three technical replicates were performed for each biological
321 replicate. Data were plotted as fold change in relation to negative control.

322 **Statistics.** For Luciferase assays groups were compared using single factor analysis of variance
323 (ANOVA) test followed by Tukey's post-hoc test. *P* values represent results from the post-hoc test.
324 To compare levels of ORF 20, ORF 50 or ORF 73 transcripts after transfection ovhv2-mirs standard
325 linear mixed effect (LME) statistical models were used. Technical replicates were entered as random
326 effects to account for the repeated sampling of the same cell line. Whether the data was test or control
327 was entered as the fixed effect. For ORF 50 and ORF 73 three independent runs were performed, and
328 this run parameter was entered as a potential confounding fixed effect prior to control/test status.
329 Examination of residuals demonstrated a normal distribution. The LME were carried out in R (version
330 2.15.0 © 2012 The R Foundation for Statistical Computing).

331 **Acknowledgements.** This project was funded by the Biotechnology and Biological Sciences
332 Research Council (BBSRC) Institute Strategic Programme Grant to The Roslin Institute. AR is in
333 receipt of a postgraduate scholarship from the Pakistan Higher Education Commission.

334 **References** 335

- 336 **Ackermann, M. (2006).** Pathogenesis of gammaherpesvirus infections. *Veterinary Microbiology* **113**,
337 211-222.
- 338 **Bartel, D. P. (2009).** MicroRNAs: Target Recognition and Regulatory Functions. *Cell* **136**, 215-233.
- 339 **Bellare, P. & Ganem, D. (2009).** Regulation of KSHV Lytic Switch Protein Expression by a Virus-
340 Encoded MicroRNA: An Evolutionary Adaptation that Fine-Tunes Lytic Reactivation. *Cell Host*
341 *& Microbe* **6**, 570-575.

342 **Cook, C. G. & Splitter, G. A. (1988).** Lytic function of bovine lymphokine-activated killer cells from a
343 normal and a malignant catarrhal fever virus-infected animal. *Vet Immunol Immunopathol*
344 **19**, 105-118.

345 **Feederle, R., Linnstaedt, S. D., Bannert, H., Lips, H., Bencun, M., Cullen, B. R. & Delecluse, H.-J.**
346 **(2011a).** A Viral microRNA Cluster Strongly Potentiates the Transforming Properties of a
347 Human Herpesvirus. *Plos Pathogens* **7**.

348 **Feederle, R., Haar, J., Bernhardt, K., Linnstaedt, S. D., Bannert, H., Lips, H., Cullen, B. R. &**
349 **Delecluse, H.-J. (2011b).** The Members of an Epstein-Barr Virus MicroRNA Cluster Cooperate
350 To Transform B Lymphocytes. *Journal of Virology* **85**, 9801-9810.

351 **Gossner, A. G., Bennet, N., Hunter, N. & Hopkins, J. (2009).** Differential expression of Prnp and Sprn
352 in scrapie infected sheep also reveals Prnp genotype specific differences. *Biochemical and*
353 *Biophysical Research Communications* **378**, 862-866.

354 **Gottwein, E. & Cullen, B. R. (2010).** A Human Herpesvirus MicroRNA Inhibits p21 Expression and
355 Attenuates p21-Mediated Cell Cycle Arrest. *Journal of Virology* **84**, 5229-5237.

356 **Grey, F., Tirabassi, R., Meyers, H., Wu, G., McWeeney, S., Hook, L. & Nelson, J. A. (2010).** A Viral
357 microRNA Down-Regulates Multiple Cell Cycle Genes through mRNA 5' UTRs. *Plos*
358 *Pathogens* **6**.

359 **Grundhoff, A. & Sullivan, C. S. (2011).** Virus-encoded microRNAs. *Virology* **411**, 325-343.

360 **Hart, J., Ackermann, M., Jayawardane, G., Russe, G., Haig, D. M., Reid, H. & Stewart, J. P. (2007).**
361 Complete sequence and analysis of the ovine herpesvirus 2 genome. *Journal of General*
362 *Virology* **88**, 28-39.

363 **Lee, K. S., Suarez, A. L., Claypool, D. J., Armstrong, T. K., Buckingham, E. M. & van Dyk, L. F. (2012).**
364 Viral Cyclins Mediate Separate Phases of Infection by Integrating Functions of Distinct
365 Mammalian Cyclins. *Plos Pathogens* **8**.

366 **Levy, C. S., Hopkins, J., Russell, G. & Dalziel, R. G. (2012).** Novel virus-encoded microRNA molecules
367 expressed by ovine herpesvirus 2 immortalized bovine T cells. *Journal of General Virology*
368 **93**, 150-154.

369 **Livak, K. J. & Schmittgen, T. D. (2001).** Analysis of relative gene expression data using real-time
370 quantitative PCR and the 2(-Delta Delta C) method. *Methods* **25**, 402-408.

371 **Meier-Trummer, C. S., Ryf, B. & Ackermann, M. (2010).** Identification of peripheral blood
372 mononuclear cells targeted by Ovine herpesvirus-2 in sheep. *Veterinary Microbiology* **141**,
373 199-207.

374 **Nascimento, R., Dias, J. D. & Parkhouse, R. M. E. (2009).** The conserved UL24 family of human
375 alpha, beta and gamma herpesviruses induces cell cycle arrest and inactivation of the
376 cyclinB/cdc2 complex. *Archives of Virology* **154**, 1143-1149.

377 **Nelson, D. D., Davis, W. C., Brown, W. C., Li, H., O'Toole, D. & Oaks, J. L. (2010).**
378 CD8(+)/perforin(+)/WC1(-) gamma delta T cells, not CD8(+) alpha beta T cells, infiltrate
379 vasculitis lesions of American bison (*Bison bison*) with experimental sheep-associated
380 malignant catarrhal fever. *Veterinary Immunology and Immunopathology* **136**, 284-291.

381 **Rehmsmeier, M., Steffen, P., Hochsmann, M. & Giegerich, R. (2004).** Fast and effective prediction
382 of microRNA/target duplexes. *Rna-a Publication of the Rna Society* **10**, 1507-1517.

383 **Reid, H. W., Buxton, D., Pow, I. & Finlayson, J. (1989).** Isolation and characterisation of
384 lymphoblastoid cells from cattle and deer affected with 'sheep-associated' malignant
385 catarrhal fever. *Res Vet Sci* **47**, 90-96.

386 **Riley, K. J., Rabinowitz, G. S., Yario, T. A., Luna, J. M., Darnell, R. B. & Steitz, J. A. (2012).** EBV and
387 human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.
388 *Embo Journal* **31**, 2207-2221.

389 **Rosbottom, J., Dalziel, R. G., Reid, H. W. & Stewart, J. P. (2002).** Ovine herpesvirus 2 lytic cycle
390 replication and capsid production. *Journal of General Virology* **83**, 2999-3002.

391 **Russell, G. C., Stewart, J. P. & Haig, D. M. (2009).** Malignant catarrhal fever: A review. *Veterinary*
392 *Journal* **179**, 324-335.

393 **Schock, A., Collins, R. A., Reid, H. W. & . (1998).** Phenotype, growth regulation and cytokine
394 transcription in Ovine Herpesvirus-2 (OHV-2)-infected bovine T-cell lines. *Veterinary*
395 *Immunology and Immunopathology* **66**, 67-68.

396 **Seto, E., Moosmann, A., Groemminger, S., Walz, N., Grundhoff, A. & Hammerschmidt, W. (2010).**
397 Micro RNAs of Epstein-Barr Virus Promote Cell Cycle Progression and Prevent Apoptosis of
398 Primary Human B Cells. *PLoS Pathogens* **6**.

399 **Tay, Y., Zhang, J. Q., Thomson, A. M., Lim, B. & Rigoutsos, I. (2009).** MicroRNAs to Nanog, Oct4 and
400 Sox2 coding regions modulate embryonic stem cell differentiation (vol 445, pg 1124, 2008).
401 *Nature* **458**, 538-538.

402 **Thonur, L., Russell, G. C., Stewart, J. P. & Haig, D. M. (2006).** Differential Transcription of ovine
403 herpesvirus 2 genes in lymphocytes from reservoir and susceptible species. *Virus Genes*
404 **2006**.

405 **Zhao, Y., Xu, H., Yao, Y., Smith, L. P., Kgosana, L., Green, J., Petherbridge, L., Baigent, S. J. & Nair, V.**
406 **(2011).** Critical Role of the Virus-Encoded MicroRNA-155 Ortholog in the Induction of
407 Marek's Disease Lymphomas. *Plos Pathogens* **7**.

408 **Ziegelbauer, J. M., Sullivan, C. S. & Ganem, D. (2009).** Tandem array-based expression screens
409 identify host mRNA targets of virus-encoded microRNAs. *Nature Genetics* **41**, 130-134.
410
411
412

413 **Figure. legends**

414 **Fig. 1**

415 **A. Genomic location of ORF 20 and ORF 50 relative to adjacent genes.**

416 Genes are indicated by open boxes, arrow head represents direction of transcription. Dotted lines
417 represent introns. The nucleotide positions representing the location of the predicted TATA box and
418 poly A site for each gene are indicated. The position of primers used for PCR and cDNA priming
419 (ORF 20) are indicated by arrows and nucleotide position. Predicted miRNA binding sequences are
420 indicated by vertical bars in the respective UTRs.

421 **B. ORF 20** Lane 1, No RT; Lane 2, cDNA primed with 35 pm primer (250 ng); Lane 3, cDNA
422 primed with 10 pm primer (66ng); Lane 4,; No template control; Lane 5, DNA positive control. Lane
423 6; Marker, Generuler 100bp

424 **C. ORF 50** Lane 1, No RT, Lane 2, cDNA primed with Oligo dT; Lane 3 , cDNA primed with
425 random primers; Lane 4, No template control; Lane 5, DNA positive control; Lane 6, Marker,
426 Generuler 1kb

427 **D. ORF73** Lane 1, No RT, Lane 2, cDNA primed with Oligo dT; Lane 3 , cDNA primed with random
428 primers; Lane 4, No template control; Lane 5, DNA positive control; Lane 6, Marker, Generuler
429 100bp

430

431

432 **Fig. 2** BHK cells (n=6) were co-transfected with: a) PGL-ORF 20, which has the 5'UTR of ORF 20
433 upstream of firefly luciferase (or with a PGL-ORF 20 in which the predicted ovhv2-miR-2 target site
434 had been mutated), pRL (which expresses renilla luciferase) and either an ovhv2-miR-2 mimic or a
435 scrambled miRNA control: b) psi-ORF 50, which has the 3'UTR of ORF 50 downstream of renilla
436 luciferase (or with a psi-ORF 50 in which the predicted ovhv2-miR-5 target site had been mutated),
437 and either an ovhv2-miR-2 mimic or a scrambled miRNA control: c) PGL-ORF 73, which has the
438 5'UTR of ORF 73 upstream of firefly luciferase (or with a PGL-ORF 73 in which the predicted
439 ovhv2-miR-8 target sites had been individually mutated), pRL (which expresses renilla luciferase) and
440 either an ovhv2-miR-8 mimic or a scrambled miRNA control 24 h post-transfection firefly luciferase
441 levels were measured, normalised to the renilla luciferase levels and expression in the control and test
442 miRNA samples compared.

443

444 **Fig. 3**

445 A) RNAhybrid analysis of the predicted target sites with the relevant miRNA.

446 mfe = mean free energy.

447 B) Sequence of ORF 73 5'UTR surrounding predicted sites 1 and 2 (underlined) the shaded box
448 represents the sequence shown to interact with ovhv2-miR-8 in A.

449

450

451

452 **Fig. 4**

453 BJ1035 cells (n=3) were transfected with control miRNA mimic or; A)

454 ovhv2-miR-5 mimic, B) ovhv2-miR-2 mimic, D) ovhv2-miR-8 mimic. Twenty four hrhr post

455 infection RNA was extracted and transcript levels of a) ORF 50, b) ORF 20 and c) ORF 73 analysed

456 by RT-qPCR (3 technical replicates per biological replicate). Levels were compared to levels in

457 control transfected cells; error bars represent the standard error of the mean levels as produced by the

458 linear mixed-effect statistical models, taking into account the technical and biological replicates.

459

460

461

462 **Table 1**
463

Gene	5'UTR	3' UTR	5' UTR targets	3' UTR targets
ORF 20	41641-41538		ovhv2-miR-2 : 41611-7	
ORF 50		79043-79196		ovhv2-miR-5 : 79161-7
ORF 73	121049-120533		ovhv2-miR-8 : 120824-18 : 120840-34	

464

465

466 Nucleotide numbers are from (GenBank, AY839756) (Hart *et al.*, 2007).

467

468

Figure 1

a




Figure 1




Figure 2




Figure 3

a

ORF 20

```
41627 5' C U CCUCCUC U 3' 41605
      ACUG UGU CCAAGAU
      UGAC ACG GGUUCUA
Ovhv2-miR-2 3' GA UGUCU CA 5'
```

mfe: -16.9 kcal/mol

ORF 50

```
79144 5' C AAAU A U C 3' 79168
      CCAG GUG CA UAACUUC
      GGUC CAC GU AUUGAAG
Ovhv2-miR-5 3' UA CGAC U 5'
```

mfe: -17.8 kcal/mol

ORF73 site 1

```
120817 5' U CCU U U 3' 120839
      GAG GCAG C CG CUGAGCC
      UUC CGUC G GC GACUCGG
Ovhv2-miR-8 3' C U A U U 5'
```

mfe: -27.4 kcal/mol

b

Site 1

AUUACGUCCCGACAUCCCGGGACCUGAGCCUGCAGCCGUCUGAGCCUUUUCUAAAA

Site 2

Figure 4

